Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 234

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 234
---
 end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended December 31, 2024 and 2023 because including them would have had an anti-dilutive effect.

9. Income taxes

For the years ended December 31, 2024 and 2023, the total net loss and comprehensive loss is as follows:

|                                          |     | Year ended December 31, 
 2024                    |   |     | 2023       |   |
|:-----------------------------------------|:----|:------------------------|:--|:----|:-----------|:--|
| Loss attributed to US foreign operations |     | (4,968,344              | ) |     | (2,023,786 | ) |
| Loss attributed to Canadian operations   |     | (6,187,172              | ) |     | (3,290,979 | ) |
| Loss before income taxes                 |     | (11,155,516             | ) |     | (5,314,765 | ) |

A reconciliation from the US statutory income tax rate of 21% to the Company’s effective income tax rate, is as follows:

|                                               |     | Year ended December 31, 
                    2024 |   |     |       2023 |   |
|:----------------------------------------------|:----|------------------------:|:--|:----|-----------:|:--|
| Income tax recovery at the statutory tax rate |     |              (2,956,212 | ) |     | (1,408,413 | ) |
| Permanent differences                         |     |                 189,075 |   |     |    796,707 |   |
| Impact of tax rate changes                    |     |                  42,865 |   |     |    436,994 |   |
| Change in valuation allowance                 |     |               2,724,272 |   |     |    174,712 |   |
|                                               |     |                       - |   |     |          - |   |

F-19 Medicus Pharma Ltd.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2024 and 2023
[expressed in United States dollars, except share amounts] The tax effect of temporary differences between US GAAP accounting and income tax accounting creating deferred income tax assets and liabilities were as follow:

|                                           |     | Year ended December 31,